Cart
sales@molnova.com
Exherin
CAS No. 229971-81-7
Exherin ( ADH-1 )
Catalog No. M13640 CAS No. 229971-81-7
Exherin (ADH-1) is a small, cyclic pentapeptide vascular-targeting agent with potential antineoplastic and antiangiogenic activities.
Purity : >98%(HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 77 | In Stock |
|
| 10MG | 128 | In Stock |
|
| 25MG | 230 | In Stock |
|
| 50MG | 383 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameExherin
-
NoteResearch use only, not for human use.
-
Brief DescriptionExherin (ADH-1) is a small, cyclic pentapeptide vascular-targeting agent with potential antineoplastic and antiangiogenic activities.
-
DescriptionExherin (ADH-1) is a small, cyclic pentapeptide vascular-targeting agent with potential antineoplastic and antiangiogenic activities; selectively and competitively binds to and blocks N-cadherin.
-
SynonymsADH-1
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number229971-81-7
-
Formula Weight570.69
-
Molecular FormulaC22H34N8O6S2
-
Purity>98%(HPLC)
-
SolubilityDMSO: 10 mM
-
SMILESC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CN=CN2)NC(=O)C)C(=O)N)C(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Perotti A, et al. Ann Oncol. 2009 Apr;20(4):741-5.
molnova catalog
related products
-
Matairesinoside
Matairesinoside is a natural product from Styrax japonica.
-
(S)-Lisofylline
(S)-Lisofylline is the inactive optical enantiomer of (R)-lisofylline which is an anti-inflammatory agent. (S)-Lisofylline is exclusively converted to pentoxifylline in human liver microsomes.
-
L-JNKI-1
L-JNKI-1 is a cell-permeable peptide inhibitor specific for JNK, it has been shown to effectively inhibit JNK activity in in vivo studies.
